Tuyển tập các báo cáo nghiên cứu về hóa học được đăng trên tạp chí sinh học quốc tế đề tài : Aberrant expression and potency as a cancer immunotherapy target of alpha-methylacyl-coenzyme A racemase in prostate cancer | Journal of Translational Medicine BioMed Central Open Access Aberrant expression and potency as a cancer immunotherapy target of alpha-methylacyl-coenzyme A racemase in prostate cancer Ichiya Honma1 2 Toshihiko Torigoe 1 Yoshihiko Hirohashi1 Hiroshi Kitamura2 Eiji Sato2 Naoya Masumori2 Yasuaki Tamura1 Taiji Tsukamoto2 and Noriyuki Sato1 Address Department of Pathology Sapporo Medical University School of Medicine Sapporo Japan and 2Department of Urology Sapporo Medical University School of Medicine Sapporo Japan Email Ichiya Honma - ichiya@ ToshihikoTorigoe - torigoe@ Yoshihiko Hirohashi - hirohash@ Hiroshi Kitamura - hkitamu@ Eiji Sato - eiji@ Naoya Masumori - masumori@ Yasuaki Tamura - ytamura@ Taiji Tsukamoto - taijit@ Noriyuki Sato - nsatou@ Corresponding author Published 9 December 2009 Received 29 January 2009 Journal of Translational Medicine 2009 7 103 doi 186 1479-5876-7-103 Accepted 9 December 2009 This article is available from http content 7 1 103 2009 Honma et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Alpha-methylacyl-CoA racemase AMACR is an enzyme playing an important role in the betaoxidation of branched-chain fatty acids and fatty acid derivatives. High expression levels of AMACR have been described in various cancers including prostate cancer colorectal cancer and kidney cancer. Because of its cancer-specific and frequent expression AMACR could be an attractive target for cytotoxic T-lymphocyte CTL -based immunotherapy for cancer. In the present study we examined the induction of AMACR-specific CTLs from prostate cancer patients peripheral blood .
